Oral News and Research

RSS

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

19 Feb 2013

Severe childhood asthma blood test hopes dashed

Blood eosinophil counts do not reliably reflect airway eosinophil concentrations in children with severe, therapy-resistant asthma, and therefore cannot be used to make therapeutic decisions, researchers report.

19 Feb 2013

Oxidative stress: the price of sucrose pain relief in neonates

Although sucrose significantly reduces the pain experienced by preterm neonates undergoing heel lance, it is associated with significant increases in adenosine triphosphate use and oxidative stress, the results of a US study indicate.

19 Feb 2013

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

One of the key reasons why children are missed by immunization programs, particularly in developing countries where Médecins Sans Frontières (MSF) works, is that the products that we currently have in their present formulation are not well-suited to the places that have the most un-immunized children. These are the most challenging contexts to work in.

19 Feb 2013

Radiographs at age 15 predict third molar impaction

Delayed root development of the mandibular third molar at age 15 years predicts subsequent impaction, according to a prospective observational study.

18 Feb 2013

Study describes pharmacological action of TZDs directly on pancreas

A scientific study published on the journal Diabetes, edited by the American Diabetes Association, describes for the first time the pharmacological action of thiazolidinediones (TZDs) —anti-diabetic drugs— directly on pancreas, the organ which produces insulin.

18 Feb 2013

Dietary impacts, health changes and oral pathogen genomic evolution

DNA preserved in calcified bacteria on the teeth of ancient human skeletons has shed light on the health consequences of the evolving diet and behaviour from the Stone Age to the modern day.

18 Feb 2013

Study identifies regions of genes linked to Beh-et's disease

Researchers don't know the exact cause of Beh-et's disease, a chronic condition that leads to oral and genital sores and serious complications such as blindness, but new research brings better understanding to what makes some people more susceptible to being affected.

16 Feb 2013

MSU to launch levetiracetam clinical trial for treatment of African children with epilepsy

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Oramed to submit new oral insulin IND with FDA

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin.

15 Feb 2013

Aspen Dental to inaugurate new office in Gallatin, TN on Feb. 21

Aspen Dental is proud to announce that a new Aspen Dental office is opening in Gallatin, TN on Thursday, Feb. 21. Located at 1007 Nashville Pike, the practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

15 Feb 2013

University of Granada’s melatonin gel effective against mucositis

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

15 Feb 2013

Aspen Dental to inaugurate new office in Canton, GA

Aspen Dental is proud to announce that a new Aspen Dental office is opening in Canton, GA on Thursday, Feb. 21. Located at 2030 Cumming Hwy., the practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

15 Feb 2013

SPI Pharma launches Actimask Ibuprofen 92S

SPI Pharma, Inc., a global leader in providing pharmaceutical ingredients and technologies for patient-friendly dosage forms, announces the launch of Actimask Ibuprofen 92S, a taste-masked Ibuprofen.

15 Feb 2013

Cambrex, Dow partner to manufacture HPMCAS for drug solubility enhancement

Cambrex and The Dow Chemical Company have executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement.

15 Feb 2013

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Innophos reports net sales of $209 million for fourth quarter 2012

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2012.

14 Feb 2013